Clinical trials / OCD
Recruiting psychedelic and ketamine trials for obsessive-compulsive disorder
8 trials registered on ClinicalTrials.gov were recruiting on 26 Oct 2026, 6 of them at sites in the United States (5 states). By substance: Ketamine / esketamine 5, Psilocybin 3.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Trials with US sites
ObservationalKetamine / esketamineNCT04480918
University of Iowa Interventional Psychiatry Service Patient Registry
- Conditions:
- Treatment Resistant Depression; Major Depressive Episode; Major Depression; Major Depressive Disorder; Bipolar Disorder; Bipolar Depression; Obsessive-Compulsive Disorder
- Sponsor:
- Mark Niciu
- Who:
- ages 18 Years to 99 Years, 1000 participants planned
- University of Iowa Health Care, Iowa City, Iowa
Phase 2Ketamine / esketamineNCT05940324
Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2) (MKET2)
- Conditions:
- Obsessive-Compulsive Disorder
- Sponsor:
- Stanford University
- Who:
- ages 18 Years to 65 Years, 150 participants planned, accepts healthy volunteers
- Department of Psychiatry & Behavioral Sciences, Stanford, California
Phase 1PsilocybinNCT06442423
Open-Label Psilocybin Study in Transdiagnostic Population
- Conditions:
- Transdiagnostic; Depression - Major Depressive Disorder; Anxiety; PTSD Symptoms; PTSD; Substance Use; Substance Use Disorder (SUD); OCD
- Sponsor:
- Yale University
- Who:
- ages 18 Years and over, 50 participants planned, accepts healthy volunteers
- Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut
Phase 1/2Ketamine / esketamineNCT06575075
Pilot Study of RR-HNK in OCD ((HNKO))
- Conditions:
- Obsessive-Compulsive Disorder
- Sponsor:
- Carolyn Rodriguez
- Who:
- ages 18 Years to 65 Years, 45 participants planned
- Stanford University School of Medicine, Palo Alto, California
ObservationalKetamine / esketamineNCT06997549
Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
- Conditions:
- Depression; OCD; Anxiety Depression
- Sponsor:
- Neuronetics
- Who:
- ages 5 Years to 100 Years, 12000 participants planned
- Neuronetics, Malvern, Pennsylvania
Phase 1PsilocybinNCT07347405
Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. (Mushroom-OCD)
- Conditions:
- Obsessive-Compulsive Disorder
- Sponsor:
- Francisco A Moreno
- Who:
- ages 18 Years and over, 30 participants planned
- The Clinical and Translational Sciences Research Center, Tucson, Arizona
Trials outside the United States
Phase 2PsilocybinNCT04882839
Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD
- Conditions:
- Obsessive-compulsive Disorder
- Sponsor:
- Beersheva Mental Health Center
- Who:
- ages 18 Years to 65 Years, 15 participants planned
- Where:
- Israel
Phase not statedKetamine / esketamineNCT05577585
Ketamine in OCD: Efficacy and Effects on Stress and Cognition (KET-OCD)
- Conditions:
- Obsessive-Compulsive Disorder; Psychiatric Disorder
- Sponsor:
- Medical University of Vienna
- Who:
- ages 18 Years and over, 60 participants planned
- Where:
- Austria